This trial is active, not recruiting.

Condition autonomic peripheral nervous system diseases
Treatments [18f]4f-mhpg, [18f]3f-phpg
Phase phase 0
Sponsor University of Michigan
Start date March 2015
End date October 2016
Trial size 16 participants
Trial identifier NCT02385877, HUM00088601


The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
[18f]4f-mhpg 4-[18F]fluoro-meta-hydroxyphenethylguanidine
IV injection of [18F]4F-MHPG
Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
[18f]3f-phpg 3-[18F]fluoro-para-hydroxyphenethylguanidine
IV injection of [18F]3F-PHPG
Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
[18f]4f-mhpg 4-[18F]fluoro-meta-hydroxyphenethylguanidine
IV injection of [18F]4F-MHPG
[18f]3f-phpg 3-[18F]fluoro-para-hydroxyphenethylguanidine
IV injection of [18F]3F-PHPG

Primary Outcomes

Composite measure based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, in minutes) of [18F]4F-MHPG and [18F]3F-PHPG in healthy subjects.
time frame: 3 months
Human radiation absorbed dose estimates based on the kinetics of the selected lead radiotracer in various organs, as extracted from whole-body PET scans.
time frame: 1 year
Number of study participants with adverse events as a measure of safety and tolerability following intravenous administration of [18F]4F-MHPG or [18F]3F-PHPG
time frame: up to 30 days after [18F]4F-MHPG or [18F]3F-PHPG injection

Eligibility Criteria

Male or female participants from 18 years up to 55 years old.

Inclusion Criteria: - Non-obese (BMI < 30) - Normal blood pressure - Normal blood lipid profile - No history of prior cardiovascular disease - Not susceptible to claustrophobia - Ability to lay flat for 90 min Exclusion Criteria: - Obesity (BMI > 30) - Risk factors for heart disease (age > 55y, hypertension, smoking, high blood pressure, high cholesterol levels, diabetes, etc.) - History of heart disease (heart attack, atrial fibrillation, ventricular tachycardia, exertional angina) - Currently using certain medications that may interact with cardiac nerves (antidepressants, cold medications, nasal decongestants, monoamine oxidase inhibitors, etc.) - Claustrophobia - Inability to lie flat for 90 min - Pregnant or breast feeding

Additional Information

Official title Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET
Principal investigator David M Raffel, PhD
Description In this study, PET imaging studies of two structurally related 18F-hydroxyphenethylguanidines, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) will be performed. All studies will be performed in normal healthy volunteers. PET stands for Positron Emission Tomography which is a type of imaging that uses a radioactive tracer. This is also called a radiotracer which is a compound linked to a radioactive element. Most compounds are short-lived, meaning that the radioactivity breaks down quickly or is excreted from the body. In the first stage of the study, dynamic PET imaging for 90 min will be done with [18F]4F-MHPG (n = 4) and [18F]3F-PHPG (n = 4). Data from these studies will assess each radiotracer's imaging properties, pharmacokinetics and metabolic breakdown in plasma. Application of tracer kinetic analysis methods to the kinetics of each tracer in heart and plasma will be studied to see if these methods can provide accurate measurements of regional nerve sympathetic nerve density in the hearts of human subjects. Results from these initial studies will be used to select the lead compound for further studies in patient populations. In the second stage of the study, whole-body PET imaging studies (n = 4) with the selected lead radiotracer will be performed to acquire data necessary for generating more accurate human radiation absorbed dose estimates.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Michigan.